Transgene and ProBioGen Expand Strategic Partnership with Additional License for AGE1.CR.pIX Cell Line
核心洞察
Transgene has broadened its existing collaboration with ProBioGen (搜索) through an additional license agreement for the AGE1.CR.pIX suspension cell line to enhance its manufacturing capabilities.
The AGE1.CR.pIX platform is a stable avian cell line derived from duck embryo primary cells, developed as an alternative to chicken eggs for large-scale vaccine production.
The cell line grows in chemically defined, animal-component-free medium and is qualified as a GMP master cell bank, supporting reproducible and scalable manufacturing.
Transgene (Euronext Paris: TNG), a biotechnology company that designs and develops virus-based immunotherapies for the treatment of cancer, and ProBioGen (搜索), a leading contract development and manufacturing organization (CDMO) in biologics, vaccines and viral vectors, announced on September 8, 2026 that they have broadened the scope of their existing collaboration. Transgene's additional license agreement for ProBioGen's AGE1.CR.pIX suspension cell line aims to enhance Transgene's manufacturing capabilities with this specialized production technology.
The expanded agreement builds on a 2024 license agreement under which Transgene licensed ProBioGen (搜索)'s AGE1.CR.pIX suspension cell line, combining ProBioGen's production technology with Transgene's manufacturing capabilities for its individualized cancer vaccine program and myvac platform.
A Scalable, Animal-Component-Free Production Platform
ProBioGen (搜索)'s AGE1.CR.pIX suspension cell line platform for vaccine production enables highly efficient manufacturing processes, supporting reliable, cost-effective production and increased productivity. The AGE1.CR.pIX cell line is a stable proliferating avian cell line derived from primary cells of a duck embryo, developed as an alternative to the use of chicken eggs for large-scale vaccine production.
The cell line is available as both a suspension and adherent cell line and has been optimized for viral vaccine production and stability. It grows in a commercially available, chemically defined medium without animal components and serves as an excellent host for a variety of different virus strains.
"A continuous cell line qualified as a GMP master cell bank, grown in chemically defined and animal-component-free medium, means every batch begins from the same fully characterized starting material," said Dr. Volker Sandig, Chief Scientific Officer at ProBioGen (搜索). "That is the foundation of a process that is reproducible, scalable and straightforward to transfer — and it lets our partners focus on the virus-product rather than the cell substrate."
Preparing for Future Clinical Needs at Scale
"We are pleased to expand the scope of our activities with ProBioGen (搜索)," said Dr. Alessandro Riva, Chairman and Chief Executive Officer of Transgene. "This additional license reflects our confidence in the technology to prepare for future clinical needs at scale."
The continued partnership between Transgene and ProBioGen (搜索) underscores a shared commitment to advancing vaccine innovations through manufacturing scalability and optimization support.
Transgene's Clinical-Stage Pipeline
Transgene's clinical-stage programs consist of a portfolio of viral vector-based immunotherapeutics. TG4050, the first individualized therapeutic vaccine based on the myvac platform, is the company's lead asset, with demonstrated proof of principle in patients in the adjuvant treatment of head and neck cancers. TG4070 (搜索), a second individualized vaccine candidate derived from the myvac platform, is in Phase 1 clinical development in combination with nivolumab in adjuvant non-small cell lung cancer (搜索) (NSCLC).
The company also has other viral vector-based assets, including BT-001, an oncolytic virus based on the Invir.IO viral backbone, which is in clinical development. Transgene also conducts innovative discovery and preclinical work aimed at developing novel viral vector-based modalities.
With Transgene's myvac platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. The myvac approach allows the generation of a virus-based immunotherapy that encodes patient-specific mutations, identified and selected through advanced artificial intelligence technologies. With its proprietary Invir.IO platform, Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses.